Silvia Boffo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Silvia Boffo has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Christopher R. Cabanski
Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA
25 shared publications - Justin Fairchild
Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA
25 shared publications - Diani Fernanda da Silva Less
Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA
24 shared publications - Sumit K. Subudhi
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
24 shared publications - Theresa LaVallee
Parker Institute for Cancer Immunotherapy, San Francisco, California
24 shared publications - Jeffrey Skolnik
Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania
23 shared publications
Latest Publications
- 16 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (42)
Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer
Immune checkpoint therapies have shown limited efficacy in metastatic castration-resistant prostate cancer (mCRPC). The AMADEUS prostate expansion cohort (NCT03651271) evaluated the efficacy, safety, and biomarkers of escalating ipilimumab doses combined with nivolumab. Patients received ipilimumab 1 milligram per kilogram (mg/kg) + nivolumab 360 mg (I1+N360), ipilimumab 3 mg/kg + nivolumab 1 mg/kg (I3+N1), or ipilimumab 5 mg/kg + nivolumab 1 mg/kg (I5+N1). Coprimary endpoints were 6-month disease control rate (DCR) and changes in tumoral CD8 percentage. Thirty-two patients were enrolled. DCRs were 33% (4 of 12) for I1+N360, 20% (1 of 5) for I3+N1, and 20% (3 of 15) for I5+N1. Across cohorts, tumoral CD8 percentage increased by a median of 5.0%. Although higher ipilimumab doses were tolerable, I1+N360 achieved similar disease control and immune activation with a more favorable safety profile. Early disease progression was associated with increased expression of a TREM2-associated myeloid gene signature, which was also significantly enriched in two independent prostate cancer datasets.
- 16 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (42)
Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer
Immune checkpoint therapies have shown limited efficacy in metastatic castration-resistant prostate cancer (mCRPC). The AMADEUS prostate expansion cohort (NCT03651271) evaluated the efficacy, safety, and biomarkers of escalating ipilimumab doses combined with nivolumab. Patients received ipilimumab 1 milligram per kilogram (mg/kg) + nivolumab 360 mg (I1+N360), ipilimumab 3 mg/kg + nivolumab 1 mg/kg (I3+N1), or ipilimumab 5 mg/kg + nivolumab 1 mg/kg (I5+N1). Coprimary endpoints were 6-month disease control rate (DCR) and changes in tumoral CD8 percentage. Thirty-two patients were enrolled. DCRs were 33% (4 of 12) for I1+N360, 20% (1 of 5) for I3+N1, and 20% (3 of 15) for I5+N1. Across cohorts, tumoral CD8 percentage increased by a median of 5.0%. Although higher ipilimumab doses were tolerable, I1+N360 achieved similar disease control and immune activation with a more favorable safety profile. Early disease progression was associated with increased expression of a TREM2-associated myeloid gene signature, which was also significantly enriched in two independent prostate cancer datasets.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S2 shows the genomic variants detected by WES and statistical analaysis of WES data.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S2 shows the genomic variants detected by WES and statistical analaysis of WES data.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S3 shows the annotation of cells evaluated by NanoString.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S3 shows the annotation of cells evaluated by NanoString.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S1 shows the processing and review of sample processing for WES, RNAseq, and MIBI.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S1 shows the processing and review of sample processing for WES, RNAseq, and MIBI.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S4 show the comparison of cell types by MIBI across sample/response groups.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S4 show the comparison of cell types by MIBI across sample/response groups.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S5 shows the expression of protein markers by cell type subsets in MIBI data.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S5 shows the expression of protein markers by cell type subsets in MIBI data.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S6 shows the TCR/BCR repertoire metrics in RNAseq data from biopsies from patients nonresponsive to combination therapy.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S6 shows the TCR/BCR repertoire metrics in RNAseq data from biopsies from patients nonresponsive to combination therapy.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S7 shows the evaluation of TLS signatures in RNAseq and MIBI samples.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Figure S7 shows the evaluation of TLS signatures in RNAseq and MIBI samples.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods 1 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Methods contains additional methods details with a data dictionary for the supplementary tables.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods 1 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Methods contains additional methods details with a data dictionary for the supplementary tables.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S9 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Tables containing sample and patient metadata, statistical results, annotation of cell types detected by MIBI, and manually reviewed variants in genes of interest.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S9 from Cellular Neighborhoods Govern Antitumor T-cell Infiltration Following Anti–CTLA-4 in Melanoma with Primary Resistance to Anti–PD-1
Supplementary Tables containing sample and patient metadata, statistical results, annotation of cell types detected by MIBI, and manually reviewed variants in genes of interest.